NCT00415064View on ClinicalTrials.gov

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

Perifosine

Perifosine given in either 50 mg or 100 mg / day

DRUG

Lenalidomide

Lenalidomide given in either 15 or 25 mg / day

DRUG

Dexamethasone

Dexamethasone given in 20 mg / day

Trial Locations (1)

48109

Ann Arbor

Sponsors

Lead Sponsor

AEterna Zentaris
All Listed Sponsors
lead

AEterna Zentaris

INDUSTRY